APRINOIA Therapeutics Archives

APRINOIA Therapeutics Announces Fast Track Designation Granted by U.S. FDA to APN-1607 for the Diagnosis of Progressive Supranuclear Palsy

Fast Track Designation follows announcement in January 2024 that the U.S. Food and Drug Administration (FDA) granted a “Study May Proceed” letter for APRINOIA’s planned Phase 3 study of APN-1607 (florzolotau (18F)) in the U.S., U.K., Europe and Asia CAMBRIDGE, Mass., May 21 (Korea Bizwire) — APRINOIA Therapeutics Inc. (“APRINOIA” or the “Company”), a clinical-stage [...]

APRINOIA Therapeutics Appoints Mark S. Shearman, Ph.D., as Chief Executive Officer

CAMBRIDGE, Mass., Aug. 28 (Korea Bizwire) — APRINOIA Therapeutics (“APRINOIA”), a global clinical-stage biopharmaceutical company developing novel therapeutics and precision diagnostics for the treatment of neurodegenerative diseases such as Alzheimer’s Disease (“AD”), Parkinson’s Disease (“PD”), and certain rare dementia and movement disorders, announced today that its Board of Directors has appointed Mark S. Shearman, Ph.D. [...]